Brain Health · Work Design · Leadership Education
A consultancy for brain health
§ V · The Library

The intellectual record.

A working library of CCG’s white papers, peer-reviewed publications, and reference frameworks. The pieces a CHRO would print and bring to a board meeting. Open downloads, no email gates.

§ I · White Papers

The CCG three-part brain economy series.

A sequenced argument for the C-suite, in three parts. Released February through April 2026.

April 2026Part III of III

Managing the Six Stressors: Evidence-Based Interventions for Workplace Brain Health

By Krystal Sexton, PhD · Founder, Cognitive Capital Group

Six organizational conditions reliably predict work-related stress: job demands, control, support, relationships, role clarity, and change communication. This paper maps concrete, evidence-based interventions to each stressor and summarizes the business outcomes they address.

March 2026Part II of III

From Insight to Action: Evidence-Based Interventions for Brain-Healthy Organizations

By Krystal Sexton, PhD · Founder, Cognitive Capital Group

The science is settled. The harder question for most leaders is operational: which interventions actually move the needle, and in what order? A three-tier framework (Cultural, Operational, Individual) for sequencing brain-healthy interventions to compound returns.

February 2026Part I of III

The Neurobiology of Performance: Why Brain Health Belongs on the C-Suite Agenda

By Krystal Sexton, PhD · Founder, Cognitive Capital Group

Twenty years of neuroscience tell a different story than the wellness category does. The conditions organizations create directly modulate the neural structures that govern judgment, creativity, and risk assessment. Brain health is no longer a human resources line item. It is a cognitive operations investment with measurable returns on productivity, decision quality, and retention.

§ II · Peer-Reviewed Publications

The published research record.

Krystal Sexton’s selected peer-reviewed work in occupational and population epidemiology.

In press (as of September 2025)

Shell Health's Journey from Epidemiology to Health Analytics

Sexton KR, Hess JW, Bhojani FB (2025). Shell Health's Journey from Epidemiology to Health Analytics. Journal of the Society of Petroleum Engineers.
In press (as of September 2025)

Engaging Stakeholders to Develop the Care for People Index for Shell Oil Company

Sexton KR, Grossmeier J, Bhojani FA, Berg H (2025). Engaging Stakeholders to Develop the Care for People Index for Shell Oil Company. American Journal of Health Promotion.
2023

Turning Evidence into Action: Workforce Mental Health in the Real World

Ballard DW, Sexton KR (2023). Turning Evidence into Action: Workforce Mental Health in the Real World. The Routledge Companion to Mental Health at Work, Edited by Arla Day and Cary L. Cooper.
Publisher
2019

Assessing Agreement in Exposure Classification between Proximity-Based Metrics and Air Monitoring Data in Epidemiology Studies of Unconventional Resource Development

Wendt Hess J, Bachler G, Momin F, Sexton K (2019). Assessing Agreement in Exposure Classification between Proximity-Based Metrics and Air Monitoring Data in Epidemiology Studies of Unconventional Resource Development. International Journal of Environmental Research and Public Health, 16(17):3055.
PubMed
2013

Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency

Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC (2013). Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research.
PubMed
2011

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, et al. (2011). A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Research and Treatment.
PubMed
2011

A review of body size and breast cancer risk in Hispanic and African American women

Sexton KR, Franzini L, Day RS, Brewster A, Vernon SW, Bondy ML (2011). A review of body size and breast cancer risk in Hispanic and African American women. Cancer.
PubMed
2009

Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer

Speers C, Tsimelzon A, Sexton K, Ramirez A, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P (2009). Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clinical Cancer Research.
PubMed
2009

Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice

Strecker T, Zhang Y, Hill JL, Li Y, Shen Q, Kim HT, Gilmer T, Sexton K, Hilsenbeck SG, Osborne CK, Brown PH (2009). Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice. Journal of the National Cancer Institute.
PubMed
2007

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, et al. (2007). Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment.
PubMed
2007

The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R (2007). The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. American Journal of Clinical Oncology.
PubMed
2006

Primary breast cancer phenotypes associated with propensity for central nervous system metastases

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006). Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer.
PubMed
2006

The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause

Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, Kramer RM (2006). The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. Journal of Supportive Oncology.
PubMed
December 2003

Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial

Early Treatment for Retinopathy of Prematurity Cooperative Group (2003). Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Archives of Ophthalmology.
PubMed